Simultaneous treatment with camptothecin and valproic acid suppresses induction of Bcl-XL and promotes apoptosis of MCF-7 breast cancer cells

Apoptosis

Volumn 14, Issue 9, 2009, Pages 1076-1085

  Arakawa, Yasuhiro ^a   Saito, Shinobu ^a   Yamada, Hisashi ^a   Aiba, Keisuke ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Bcl XL; Camptothecin; Histone deacetylase inhibitor; Simultaneous treatment; Valproic acid

Indexed keywords

CAMPTOTHECIN; CASPASE; GOSSYPOL; PROTEIN BCL XL; SMALL INTERFERING RNA; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BCL-X PROTEIN; BREAST NEOPLASMS; CAMPTOTHECIN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOBLOTTING; MEMBRANE POTENTIAL, MITOCHONDRIAL; RNA, SMALL INTERFERING; VALPROIC ACID;

EID: 68349146398     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-009-0384-0     Document Type: Article

References (28)

1. EA Perez DW Hillman JA Mailliard 2004 Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both J Clin Oncol 22 14 2849 2855
2. GP Stathopoulos D Tsavdaridis NA Malamos 2005 Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study Cancer Chemother Pharmacol 56 5 487 491
3. Y Xu MA Villalona-Calero 2002 Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity Ann Oncol 13 12 1841 1851
4. CJ Phiel F Zhang EY Huang MG Guenther MA Lazar PS Klein 2001 Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J Biol Chem 276 39 36734 36741
5. M Gottlicher S Minucci P Zhu 2001 Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J 20 24 6969 6978
6. MS Kim M Blake JH Baek G Kohlhagen Y Pommier F Carrier 2003 Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA Cancer Res 63 21 7291 7300
7. DC Marchion E Bicaku AI Daud V Richon DM Sullivan PN Munster 2004 Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid J Cell Biochem 92 2 223 237
8. DC Marchion E Bicaku AI Daud DM Sullivan PN Munster 2005 In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates Mol Cancer Ther 4 12 1993 2000
9. E Devarajan AA Sahin JS Chen 2002 Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance Oncogene 21 57 8843 8851
10. RN Winter A Kramer A Borkowski N Kyprianou 2001 Loss of caspase-1 and caspase-3 protein expression in human prostate cancer Cancer Res 61 3 1227 1232
11. RU Janicke ML Sprengart MR Wati AG Porter 1998 Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis J Biol Chem 273 16 9357 9360
12. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55
13. ST Smiley M Reers C Mottola-Hartshorn 1991 Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1 Proc Natl Acad Sci USA 88 9 3671 3675
14. Y Meng W Tang Y Dai 2008 Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa Mol Cancer Ther 7 7 2192 2202
15. XH Yang TL Sladek X Liu BR Butler CJ Froelich AD Thor 2001 Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis Cancer Res 61 1 348 354
16. JE Bolden MJ Peart RW Johnstone 2006 Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 9 769 784
17. NH Chobanian VL Greenberg JM Gass CP Desimone JR Van Nagell SG Zimmer 2004 Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status Anticancer Res 24 2B 539 545
18. A Kuendgen M Schmid R Schlenk 2006 The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia Cancer 106 1 112 119
19. M Adachi Y Zhang X Zhao 2004 Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells Clin Cancer Res 10 11 3853 3862 (Pubitemid 38697621)
20. MJ Peart GK Smyth RK van Laar 2005 Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors Proc Natl Acad Sci USA 102 10 3697 3702
21. A Rada-Iglesias S Enroth A Ameur 2007 Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes Genome Res 17 6 708 719
22. RL Hayward JS Macpherson J Cummings BP Monia JF Smyth DI Jodrell 2003 Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity Clin Cancer Res 9 7 2856 2865
23. Y Sowa T Orita S Minamikawa 1997 Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites Biochem Biophys Res Commun 241 1 142 150 (Pubitemid 28033553)
24. V Sandor A Senderowicz S Mertins 2000 P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 Br J Cancer 83 6 817 825
25. PR Walker J Leblanc C Carson M Ribecco M Sikorska 1999 Neither caspase-3 nor DNA fragmentation factor is required for high molecular weight DNA degradation in apoptosis Ann NY Acad Sci 887 48 59
26. SA Lakhani A Masud K Kuida 2006 Caspases 3 and 7: key mediators of mitochondrial events of apoptosis Science 311 5762 847 851
27. E Gupta X Wang J Ramirez MJ Ratain 1997 Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital Cancer Chemother Pharmacol 39 5 440 444
28. P Munster D Marchion E Bicaku 2007 Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study J Clin Oncol 25 15 1979 1985